LLY
Eli Lilly and Company
LLY has the edge over SDGR overall, supported by stronger fundamentals and lower modeled downside.
SDGR
Schrödinger, Inc.
SDGR trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SDGR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
SDGR's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SDGR PE Valuation
SDGR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over SDGR on the outlook, with more favorable earnings and revenue expectations.
SDGR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SDGR's profitability to improve, with its earnings and revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over SDGR on earnings quality, reporting a profit while its opponent remains loss making.
SDGR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.78 | +$1.63 |
| Q2 2026 | -$0.73 | +$1.75 |
| Q1 2026 | -$1.40 | +$1.23 |
| Q4 2025 | -$1.41 | +$1.16 |
| Q3 2025 | -$2.41 | +$0.02 |
| Q2 2025 | -$2.48 | +$0.29 |
| Q1 2025 | -$2.63 | -$0.66 |
| Q4 2024 | -$2.57 | -576% |
SDGR is still losing money, but far less than before: $0.78 per share over the past year, against $2.77 at its worst in mid-2024.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over SDGR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over SDGR on profitability, with a higher operating margin.
SDGR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $64.5M | +19% |
| Q2 2026 | $58.9M | +7.5% |
| Q1 2026 | $58.6M | -1.6% |
| Q4 2025 | $87.2M | -1.2% |
| Q3 2025 | $54.3M | +54% |
| Q2 2025 | $54.8M | +16% |
| Q1 2025 | $59.6M | +63% |
| Q4 2024 | $88.3M | +19% |
SDGR's revenue is recovering but still below its 2024 peak: $64M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -41% | +44 points |
| Q2 2026 | -71% | +26 points |
| Q1 2026 | -83% | +2.2 points |
| Q4 2025 | -20% | +3.8 points |
| Q3 2025 | -85% | +109 points |
| Q2 2025 | -97% | +15 points |
| Q1 2025 | -85% | +99 points |
| Q4 2024 | -23% | +17 points |
SDGR's operating margin was −41% last quarter, up 44 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over SDGR on cash generation, producing positive trailing cash flow while its opponent burns cash.
SDGR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$48.9M | +$13.5M |
| Q2 2026 | -$34.4M | +$18.1M |
| Q1 2026 | -$17.3M | -112% |
| Q4 2025 | -$16.1M | +$15.9M |
| Q3 2025 | -$62.4M | -$27.8M |
| Q2 2025 | -$52.5M | +$2.2M |
| Q1 2025 | $143.5M | +$186.8M |
| Q4 2024 | -$32M | +$7.7M |
SDGR has burned cash in almost every quarter: −$117M over the past year, against −$3M the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SDGR Net Leverage
SDGR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SDGR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.5 | Neutral |
| Stochastic | 75.2 | Neutral |
SDGR's weekly RSI is 69 (neutral) and its Stochastic is 75 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SDGR PE vs Healthcare Sector
| Metric | SDGR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SDGR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
SDGR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.6 | 12% above |
| 20 week MA | $22.1 | 39% above |
| 50 week MA | $17.4 | 77% above |
| 100 week MA | $19.3 | 60% above |
| 200 week MA | $23.4 | 32% above |
SDGR has climbed back above all five of its weekly moving averages, and it's now 32% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
SDGR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $31.9 | $84.0 | +163% |
| 2021 | $84.0 | $35.9 | -57% |
| 2022 | $35.9 | $18.9 | -47% |
| 2023 | $18.9 | $35.8 | +90% |
| 2024 | $35.8 | $19.8 | -45% |
| 2025 | $19.8 | $18.3 | -7.4% |
| 2026 YTD | $18.3 | $30.9 | +68% |
SDGR has the edge over LLY on returns for 2026, with the stronger performance.